#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Metformin with Extended Release in the Treatment of Prediabetes

The benefit of metformin in preventing the development of diabetes in people with prediabetes has been demonstrated in clinical studies. However, these studies evaluated immediate-release metformin, not its extended-release form (XR). Therefore, the results of an observational study conducted at Polish and Hungarian centers, which examined the efficacy and safety of metformin XR in patients with prediabetes, are important in this context. It is also necessary to add that in our country, no drug containing this active substance has yet received an approved indication for the therapy of patients with prediabetes.
Source: Modern Treatment of Diabetes 2. 11. 2022

News Brentuximab Vedotin in Patients with R/R cHL in the Real World: What to Expect?

How does brentuximab vedotin (BV) perform as maintenance therapy in real-world practice for patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL) who have undergone autologous hematopoietic stem cell transplantation (HCT) and are at high risk of its failure? This question was posed by authors from King Abdullah International Medical Research Center at King Saud bin Abdulaziz University for Health Sciences in Riyadh. They presented their findings in a poster session at this year's virtual European Society for Blood and Marrow Transplantation (EBMT 2022) congress.
Source: Hematologic Malignancies 27. 4. 2022

News Long-term survival of a 50-year-old man with metastatic pancreatic cancer on a combination of nal-IRI + 5-FU/LV in 2nd line treatment − case study

A recently published case study from the Czech Republic describes a patient with progression of pancreatic cancer following surgical treatment and adjuvant chemotherapy, who achieved a one-year survival with good quality of life on a combination of nal-IRI + 5-FU/LV after the failure of gemcitabine + nab-paclitaxel in the 1st line of palliative treatment.
Source: Treatment of Gastrointestinal Carcinomas 3. 6. 2024

News Satisfaction of Patients Treated with Platinum Derivatives with Antiemetic Therapy

The fixed oral combination of netupitant with palonosetron (NEPA) is used for the prevention of nausea and vomiting induced by cytotoxic chemotherapy. A prospective German study evaluated the benefit of this therapy on the quality of life of patients treated with platinum derivatives.
Source: Antiemetic Therapy 23. 9. 2020

News Candesartan Could Ameliorate the Cytokine Storm in COVID-19 Infection

Scientists from Bethesda, USA, experimentally found the upregulation of the same genes during COVID-19 infection as with the action of glutamate (simulating aging and Alzheimer's disease) and the normalization of their expression by candesartan. Considering that many of these genes are involved in the cytokine storm in COVID-19, the mentioned results support the hypothesis that sartans − or at least candesartan − could mitigate the cytokine storm in patients with severe COVID-19.
Source: Sartans in the Treatment of Hypertension 27. 1. 2021

News L. reuteri DSM 17938 in Infant Nutrition and Its Impact on the Gut Microbiota of Infants Born by Cesarean Section

The work of the Swiss-Greek team published in the Journal of Pediatric Gastroenterology and Nutrition focused on comparing the effect of infant formula containing Lactobacillus reuteri DSM 17938 on the microbiota of children born by cesarean section or vaginal delivery.
Source: GI, colic and microbiome 15. 5. 2020

News Human Papillomavirus in Adults – HPV Does Not Choose Gender

A significant part of the population is exposed to human papillomaviruses (HPV) throughout their lives. In recent years, there has been a global effort to increase vaccination coverage not only among children and adolescents who have not yet been vaccinated but also among adult women and men who could benefit from it, including those who have likely already encountered HPV.
Source: Regular Vaccination 31. 5. 2024

News Cardiovascular System Affection in Children with Noonan Syndrome

Noonan syndrome is a genetically conditioned disease classified among the so-called RASopathies, caused by a germline mutation in the genes of the RAS/MAPK signaling pathway. Among other things, children with this disease typically present with cardiovascular system involvement.
Source: Growth Disorders 13. 12. 2021

News Residual Pulmonary Hypertension After Endarterectomy: How Common Is It?

Pulmonary endarterectomy is the only potentially curative option in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH). What are its outcomes and in what percentage of cases does it lead to complete cure? A meta-analysis, significantly contributed to by Czech experts, was dedicated to the improvement of signs and symptoms of CTEPH after performing endarterectomy.
Source: Pulmonary hypertension (CTEPH, PAH) 23. 11. 2020

News Idiopathic Thrombocytopenic Purpura with SARS-CoV-2 Infection

To date, 45 cases of idiopathic (autoimmune) thrombocytopenic purpura (ITP) in individuals with confirmed SARS-CoV-2 infection have been published in the literature. In September 2020, a review summarizing the clinical profile and treatment outcomes of ITP in these individuals was released.
Source: Immune Thrombocytopenia 27. 10. 2020

News Bilastine as a reliable helper in the treatment of allergic rhinoconjunctivitis and urticaria even in younger children

Until recently, bilastine was indicated for the treatment of allergic rhinoconjunctivitis and urticaria only in patients over 12 years of age. However, current findings from valid studies demonstrate the safety and efficacy of its use even in younger individuals.
Source: Allergic Reactions 21. 7. 2021

News A Decade of Therapy Targeting B Lymphocytes in MS

Ocrelizumab is not only a pioneer but also a highly effective and still promising modality for the treatment of multiple sclerosis (MS) with excellent patient adherence and persistence.
Source: Neurology - Multiple Sclerosis 3. 1. 2024

News Hydrotherapy in the Treatment of Non-Healing Wounds

For the treatment of wounds, it is crucial how they are managed during the cleaning and granulation phases. For most non-healing wounds, so-called Hydrotherapy (treatment with hydroresponsive dressings) is suitable, which involves just two steps. The essence of Hydrotherapy is the maintenance of a moist environment and, if possible, a constant temperature in the wound.
Source: Wound Healing 10. 2. 2021

News Comparison of the Effectiveness of Different Types of Toothbrushes in Orthodontic Patients

The aim of the study cited below was to evaluate the efficiency of a manual orthodontic brush, an electric toothbrush with an oscillating head, and a sonic toothbrush in controlling plaque, gingivitis, and interproximal bleeding in patients undergoing orthodontic treatment with fixed appliances and to compare their relative effectiveness.
Source: Dental Care 10. 5. 2023

News Classification and Management of Chronic Wounds

Chronic wounds are common comorbidities that increase the morbidity and mortality of patients. Common types of chronic wounds on the lower extremities include arterial, venous, and diabetic ulcers, as well as pressure ulcers. Despite their frequent occurrence, they are often poorly treated. In addition to diagnosing the etiology of chronic wounds and specific therapies, moist wound healing plays a crucial role in the treatment, such as the application of hydrocolloids and hydrogels.
Source: Wound Healing 23. 8. 2021

News Bimekizumab in the treatment of moderate to severe hidradenitis suppurativa – another approved indication for this biological agent

In May, the primary results of the BE HEARD I and II studies evaluating the efficacy and safety of the IL-17A and IL-17F inhibitor bimekizumab in the treatment of moderate to severe hidradenitis suppurativa (HS) in adults were published in The Lancet. This is the first publication of the results of these Phase III studies. Based on these findings, the European Medicines Agency (EMA) approved bimekizumab (which is currently approved for the treatment of plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis) for the treatment of HS in adults who have not responded adequately to conventional systemic therapy.
Source: Psoriasis 1. 7. 2024

News News in COPD Treatment Recommendations in a Nutshell

We present an overview of the most important changes in the annually updated recommendations of the Global Initiative for Chronic Obstructive Lung Disease (GOLD).
Source: Treatment of Asthma and COPD 6. 4. 2022

News Streptococcus pneumoniae Serotype 3 Continues to Be the Most Frequent Cause of Invasive Pneumococcal Diseases in the Czech Republic

After 2 years influenced by the COVID-19 pandemic, the number of cases of invasive pneumococcal diseases (IPD) has returned to pre-2020 levels. Serotype 3 remains the most frequent cause of IPD for the twelfth consecutive year.
Source: Regular Vaccination 26. 10. 2023

News DPP-4 Inhibitors May Prevent SARS-CoV-2 Entry into Cells

Since the new type of coronavirus SARS-CoV-2 utilizes the DPP-4 receptor to enter human cells, DPP-4 inhibition by gliptins could represent a potential approach to pharmacological treatment of COVID-19 caused by this coronavirus.
Source: Diabetes 3. 8. 2020

News Current Recommendations for Using SGLT2 Inhibitors in Patients with Renal or Cardiovascular Risk

Type 2 diabetes mellitus (DM2) is a serious chronic metabolic disease whose prevalence has been increasing in recent years. Currently, diabetics make up approximately 8−10% of the population. The therapy is traditionally focused primarily on suppressing the development and progression of diabetic complications, but modern antidiabetics have also brought other unprecedented benefits. The following text summarizes the role of gliflozins in the pharmacotherapy of DM2 in light of current recommendations.
Source: Heart Failure 20. 8. 2021

News Can Antihypertensives Reduce the Risk of Dementia? The Answer Suggests the Angiotensin Hypothesis and a Post-Hoc Analysis of an Observational Study

The use of antihypertensives that do not reduce angiotensin II levels, such as angiotensin receptor blockers (ARBs, i.e., sartans) and calcium channel blockers (CCBs), has been associated with a lower risk of dementia in studies. In the research cited below, the authors aimed to determine whether this effect persists longer than the follow-up period in previous studies.
Source: Sartans in the Treatment of Hypertension 14. 8. 2023

Journal articles Lung cancer prevention and prevention programs

Author of the article: Lubomír Tulinský Source: Časopis lékařů českých | 4/2023 19. 9. 2023

News Frequent Nausea During Chemotherapy Despite Antiemetic Prophylaxis

Current clinical research has focused on vomiting as a primary issue in the occurrence of CINV (chemotherapy-induced nausea and vomiting) and, using recommended antiemetic prophylaxis, this problem has been relatively well managed. However, the incidence and impact of nausea are underreported. We present the results of an observational study that evaluated the incidence of nausea in patients undergoing chemotherapy.
Source: Antiemetic Therapy 9. 12. 2020

News Limits of Glycated Hemoglobin and the Importance of Other Glycated Proteins

Glycated hemoglobin is a gold standard in the diagnosis and management of diabetes treatment. However, its disadvantages include numerous factors that can cause false increases or decreases in its levels. Therefore, the scientific community is also interested in researching other glycated proteins that could be used in diabetes control. So, what should we keep in mind when collecting glycated hemoglobin?
Source: Modern Treatment of Diabetes 17. 2. 2022

News How to Navigate the Challenges of Anticoagulant Therapy in Pregnant Women − A Case Study

Every carrier of a mechanical heart valve is also on anticoagulant therapy. Warfarin is most commonly used for this purpose, but it is not suitable during pregnancy due to the risk of embryopathy. So how should we approach patients with artificial valves who wish to become pregnant? The following case study presents one option.
Source: Thromboprophylaxis 3. 1. 2024

1 46 47 48 49 50 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#